JP2024533371A5 - - Google Patents

Info

Publication number
JP2024533371A5
JP2024533371A5 JP2024515376A JP2024515376A JP2024533371A5 JP 2024533371 A5 JP2024533371 A5 JP 2024533371A5 JP 2024515376 A JP2024515376 A JP 2024515376A JP 2024515376 A JP2024515376 A JP 2024515376A JP 2024533371 A5 JP2024533371 A5 JP 2024533371A5
Authority
JP
Japan
Prior art keywords
formulas
nucleotides
nucleotide
nucleotide sequence
sina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533371A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/042808 external-priority patent/WO2023039005A2/en
Publication of JP2024533371A publication Critical patent/JP2024533371A/ja
Publication of JP2024533371A5 publication Critical patent/JP2024533371A5/ja
Pending legal-status Critical Current

Links

JP2024515376A 2021-09-08 2022-09-07 修飾された短い干渉核酸(siNA)分子及びそれらの使用 Pending JP2024533371A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163241935P 2021-09-08 2021-09-08
US63/241,935 2021-09-08
PCT/US2022/042808 WO2023039005A2 (en) 2021-09-08 2022-09-07 Modified short interfering nucleic acid (sina) molecules and uses thereof

Publications (2)

Publication Number Publication Date
JP2024533371A JP2024533371A (ja) 2024-09-12
JP2024533371A5 true JP2024533371A5 (cg-RX-API-DMAC7.html) 2025-09-16

Family

ID=83506451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515376A Pending JP2024533371A (ja) 2021-09-08 2022-09-07 修飾された短い干渉核酸(siNA)分子及びそれらの使用

Country Status (9)

Country Link
US (2) US12454691B2 (cg-RX-API-DMAC7.html)
EP (1) EP4399217A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024533371A (cg-RX-API-DMAC7.html)
KR (1) KR20240099159A (cg-RX-API-DMAC7.html)
CN (1) CN118201942A (cg-RX-API-DMAC7.html)
AU (1) AU2022344131A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231695A1 (cg-RX-API-DMAC7.html)
TW (1) TW202320809A (cg-RX-API-DMAC7.html)
WO (1) WO2023039005A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118271378A (zh) * 2022-12-29 2024-07-02 中国科学院深圳先进技术研究院 一种糖环修饰的核苷亚磷酰胺单体及其制备方法和应用
CN119836430A (zh) * 2023-05-12 2025-04-15 北京炫景瑞医药科技有限公司 修饰的核苷类似物及其用途与含核苷酸类似物的双链寡核苷酸及其用途
CN121772930A (zh) * 2023-07-31 2026-03-31 基愈治疗股份有限公司 N-乙酰基-半乳糖胺(galnac)和寡核苷酸的缀合物以及其用途
CN117534717A (zh) * 2024-01-09 2024-02-09 凯莱英生命科学技术(天津)有限公司 5′-(e)-乙烯基磷酸酯的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218108B1 (en) * 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
CA2522349A1 (en) * 2003-04-17 2004-11-04 Alnylam Pharmaceuticals, Inc. Protected monomers
CA2701845A1 (en) * 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures
WO2011094953A1 (en) 2010-02-08 2011-08-11 F. Hoffmann-La Roche Ag Compounds for the treatment and prevention of influenza
WO2011139702A2 (en) 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
WO2011139699A2 (en) * 2010-04-28 2011-11-10 Isis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
ES2952714T3 (es) 2013-06-26 2023-11-03 Janssen Pharmaceuticals Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
WO2018013999A1 (en) 2016-07-15 2018-01-18 Am Chemicals Llc Non-nucleosidic solid supports and phosphoramidite building blocks for oligonucleotide synthesis
JOP20170056B1 (ar) 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
WO2018045317A1 (en) 2016-09-02 2018-03-08 Dicerna Pharmaceuticals, Inc. 4'-phosphate analogs and oligonucleotides comprising the same
EP3735252A4 (en) * 2018-01-04 2021-10-06 Avidity Biosciences, Inc. HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF
WO2019217397A2 (en) 2018-05-07 2019-11-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for improving strand biased
US20200147124A1 (en) 2018-11-08 2020-05-14 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
KR20210126636A (ko) 2019-02-14 2021-10-20 알리고스 테라퓨틱스 인코포레이티드 이환식 설폰아마이드
IL286902B2 (en) 2019-04-03 2025-03-01 Aligos Therapeutics Inc Pyrrole compounds
EP3956331A4 (en) 2019-04-17 2023-01-11 Aligos Therapeutics, Inc. BICYCLIC AND TRICYCLIC COMPOUNDS
WO2021119325A1 (en) * 2019-12-12 2021-06-17 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20240352464A1 (en) * 2023-03-07 2024-10-24 Aligos Therapeutics, Inc. Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof

Similar Documents

Publication Publication Date Title
JP7792371B2 (ja) GalNAc誘導体
US10889817B2 (en) Oligonucleotide therapy for Leber Congenital Amaurosis
JP6752151B2 (ja) 遺伝子サイレンシングにおいて低下したoff−target効果を有するunaオリゴマー
JP2023123469A (ja) B型肝炎ウイルス感染のためのRNAi薬
TW202113079A (zh) 經修飾之間隙子寡核苷酸及其使用方法
JP2018520685A (ja) B型肝炎ウイルスに対する組成物および薬剤ならびにその使用
CN113507920A (zh) 用于乙型肝炎病毒感染的RNAi剂
JP2019515663A5 (cg-RX-API-DMAC7.html)
JP2023509870A (ja) Hbvの処置のためのhbvを標的とする治療用オリゴヌクレオチドとtlr7アゴニストとの医薬組合せ
WO2017106244A1 (en) Compositions and methods for regulatable antibody expression
IL277970B2 (en) Oligomeric compounds comprising modified oligonucleotides and conjugated groups for use in the treatment of end-stage renal disease, chronic kidney disease and coronary artery disease
JP2021534154A5 (cg-RX-API-DMAC7.html)
CN119654412A (zh) 激活补体因子h表达的寡核苷酸调节剂
JP2025072578A (ja) B型肝炎ウイルス感染症を処置するためのsept9阻害剤の使用
CA3178591A1 (en) Immunosuppressive agents and viral delivery re-dosing methods for gene therapy
JP2023530379A5 (cg-RX-API-DMAC7.html)
JP2023509872A (ja) Hbvを標的とする抗ウイルス剤及び/又はhbvの処置のための免疫調節剤の医薬組合せ
US20230383296A1 (en) Modified gapmer oligomers and methods of use thereof
US11898145B2 (en) Enhanced oligonucleotides for inhibiting RTEL1 expression
JP2022510346A5 (cg-RX-API-DMAC7.html)
CN119709734A (zh) 用于干扰乙型肝炎病毒的siRNA及其用途
CN121793974A (zh) 用于治疗肌少症的组合物和方法
HK40036011A (en) Galnac derivatives
HK40062579A (en) Rnai agents for hepatitis b virus infection
WO2024235124A1 (zh) 修饰的核苷类似物及其用途与含核苷酸类似物的双链寡核苷酸及其用途